Synthetic peptide, corresponding to Human IKB-beta.
Conjugation:
Unconjugated
Alternative Names:
NF-kappa-B inhibitor beta, NF-kappa-BIB, I-kappa-B-beta, IkB-B, IkB-beta, IkappaBbeta, Thyroid receptor-interacting protein 9, TR-interacting protein 9, TRIP-9, NFKBIB, IKBB, TRIP9
The NF-kappaB/Rel transcription factors are present in the cytosol in an inactive state complexed with the inhibitory IkappaB proteins. Activation occurs via phosphorylation of IkappaBalpha at Ser32 and Ser36 followed by proteasome-mediated degradation that results in the release and nuclear translocation of active NF-kappaB. IkappaBalpha phosphorylation and resulting Rel-dependent transcription are activated by a highly diverse group of extracellular signals including inflammatory cytokines, growth factors, and chemokines. Kinases that phosphorylate IkappaB at these activating sites have been identified. The regulation of IkappaBbeta and IkappaBepsilon is similar to that of IkappaBalpha. However, the phosphorylation and ubiquitin-mediated degradation of these proteins occurs with much slower kinetics. IKK phosphorylation of IkappaBbeta occurs at Ser19 and Ser23, while IkappaBepsilon can be phosphorylated at Ser18 and Ser22.
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Form:
Rabbit IgG, 1mg/ml in PBS with 0.02% sodium azide, 50% glycerol, pH7.2
Application Dilute:
WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:100~1:500
Application Notes:
IKB-beta (Y188) polyclonal antibody detects endogenous levels of IKB-beta protein.
* VAT and and shipping costs not included. Errors and price changes excepted
